Key Takeaway: The article discusses a 48-month open-label trial evaluating the long-term efficacy and safety of Arimoclomol in patients with Niemann-Pick Type C. The findings presented at the 21st Annual WORLDSymposium highlight the potential benefits of this treatment. The data suggests a positive outlook for patients receiving Arimoclomol.
Price reaction · baseline $7.84 (2025-01-31 close) · hit pre-market · 3 other ZVRA headline(s) in the window, move may be shared
day 0 close · peak
-2.4%
Market Sentiment Analysis
POSITIVE FACTORS
Long-term efficacy data from a 48-month trial is promising.
Arimoclomol shows potential benefits for Niemann-Pick Type C patients.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+71%
120-day peak, hindsight
Typical move
10.7%
average across 6 past catalysts
Lead asset
KP415
Phase 3 · ADHD
Full Press Release Details
< Medical Publications and Presentations
Long-term Efficacy and Safety Evaluation of Arimoclomol Treatment in Patients with Niemann-Pick Type C – Data From 48 Months Open Label Trial
21st Annual WORLDSymposium - 02/05/2025
Download PDF
Download PDF
Frequently Asked Questions
What is the focus of the 48-month trial?
The trial focuses on the long-term efficacy and safety of Arimoclomol in Niemann-Pick Type C patients.
Where were the trial results presented?
The trial results were presented at the 21st Annual WORLDSymposium.
What does Arimoclomol aim to treat?
Arimoclomol aims to treat Niemann-Pick Type C disease.